ARIAD Announces Ponatinib Presentations at Annual American Society of Hematology Meeting

December 3, 2012

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial will be featured in five presentations – two oral and three posters.

PACE Trial: 12-Month Follow Up in Chronic Phase Patients
 
Title: A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Oral Session: 632. Chronic Myeloid Leukemia - Therapy I Session
Date & Time: Sunday, December 9, 2012, 4:30 p.m.
Abstract No: 163
Presenter: Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center)
Location: Georgia World Congress Center, A411-A412
 
PACE Trial: Efficacy and Safety in Advanced Phase Patients
 
Title: Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
Oral Session: 632. Chronic Myeloid Leukemia - Therapy II Session
Date and Time: Tuesday, December 11, 2012 at 8:00 a.m.
Abstract No.: 915
Presenter: Hagop M. Kantarjian, M.D. (The University of Texas MD Anderson Cancer Center)
Location: Georgia World Congress Center, A411-A412
 
PACE Trial: Results According to Prior Tyrosine Kinase Inhibitor Therapy
 
Title: Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP‐CML): Results from the PACE Trial
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3749
Presenter: Dong-Wook Kim, M.D., Ph.D. (Mary’s Hospital, The Catholic University of Korea)
Location: Georgia World Congress Center, Hall B1-B2
 
PACE Trial: Molecular Response Data
 
Title: Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3763
Author: Andreas Hochhaus, M.D., University Medical Center Jena in Germany
Location: Georgia World Congress Center, Hall B1-B2
 
PACE Trial: Multivariate Analysis of Parameters
 
Title: Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3747
Presenter: Michael Mauro, M.D. (Oregon Health & Science University)
Location: Georgia World Congress Center, Hall B1-B2
 
Phase 1 Trial: Long-term Results
 
Title: Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study
Poster Session: 632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time: Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.: 3743
Presenter: Michael Deininger, M.D., Ph.D. (University of Utah School of Medicine Huntsman Cancer Institute)
Location: Georgia World Congress Center, Hall B1-B2
         
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted medicines for drug-resistant or difficult-to-treat cancers, including chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial will be featured in five presentations – two oral and three posters.

PACE Trial: 12-Month Follow Up in Chronic Phase Patients

 

Title:

 

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Oral Session:

 

632. Chronic Myeloid Leukemia - Therapy I Session

Date & Time:

 

Sunday, December 9, 2012, 4:30 p.m.

Abstract No.:

 

163

Presenter:

 

Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center)

Location:

 

Georgia World Congress Center, A411-A412

 

PACE Trial: Efficacy and Safety in Advanced Phase Patients

 

Title:

 

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Oral Session:

 

632. Chronic Myeloid Leukemia - Therapy II Session

Date and Time:

 

Tuesday, December 11, 2012 at 8:00 a.m.

Abstract No.:

 

915

Presenter:

 

Hagop M. Kantarjian, M.D. (The University of Texas MD Anderson Cancer Center)

Location:

 

Georgia World Congress Center, A411-A412

 

PACE Trial: Results According to Prior Tyrosine Kinase Inhibitor Therapy

 

Title:

 

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CPCML): Results from the PACE Trial

Poster Session:

 

632. Chronic Myeloid Leukemia - Therapy: Poster III

Date & Time:

 

Monday, December 10, 2012, 6:00 – 8:00 p.m.

Abstract No.:

 

3749

Presenter:

 

Dong-Wook Kim, M.D., Ph.D. (Mary’s Hospital, The Catholic University of Korea)

Location:

 

Georgia World Congress Center, Hall B1-B2

 

PACE Trial: Molecular Response Data

 

Title:

 

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Poster Session:

 

632. Chronic Myeloid Leukemia - Therapy: Poster III

Date & Time:

 

Monday, December 10, 2012, 6:00 – 8:00 p.m.

Abstract No.:

 

3763

Author:

 

Andreas Hochhaus, M.D., University Medical Center Jena in Germany

Location:

 

Georgia World Congress Center, Hall B1-B2

 

PACE Trial: Multivariate Analysis of Parameters

 

Title:

 

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Poster Session:

 

632. Chronic Myeloid Leukemia - Therapy: Poster III

Date & Time:

 

Monday, December 10, 2012, 6:00 – 8:00 p.m.

Abstract No.:

 

3747

Presenter:

 

Michael Mauro, M.D. (Oregon Health & Science University)

Location:

 

Georgia World Congress Center, Hall B1-B2

 

Phase 1 Trial: Long-term Results

 

Title:

 

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Poster Session:

 

632. Chronic Myeloid Leukemia - Therapy: Poster III

Date & Time:

 

Monday, December 10, 2012, 6:00 – 8:00 p.m.

Abstract No.:

 

3743

Presenter:

 

Michael Deininger, M.D., Ph.D. (University of Utah School of Medicine Huntsman Cancer Institute)

Location:

 

Georgia World Congress Center, Hall B1-B2

   

 

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted medicines for drug-resistant or difficult-to-treat cancers, including chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.